


<b>Wei-Yu Kao, M.D. &amp;Ph.D.</b>	
Director, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan	
Assistant professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan	
Convener, Hepatocellular Carcinoma Team, Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan	

Doctor Wei-Yu Kao's research interests are viral hepatitis (particularly HBV and HCV), nonalcoholic fatty liver disease, liver cirrhosis and hepatocellular carcinoma (particularly local ablation for small HCC). He has demonstrated compliance with the Taiwan Academy of Tumor Ablation accreditation criteria for professional operator on liver tumor ablation since 2016. He has completed Samsung Medical Center Image-guided Tumor Ablation Training Course in 2015 and Juntendo University International RFA Training Program in 2016. He is a reviewer of PLOS ONE, BMC Gastroenterology, International Journal of Oncology, Journal of Microbiology, Immunology and Infection, Journal of the Formosan Medical Association, Liver International, Journal of Gastroenterology and Hepatology, Digestive Diseases, Hepatology International, European Radiology, Cancers and Alimentary Pharmacology & Therapeutics. He is an editorial board of BMC Gastroenterology. He has authored and co-authored 54 peer-review articles and presented 46 oral and poster presentations in conferences.

1999/9-2006/6	M.D., Faculty of Medicine, School of Medicine, Taipei Medical University, Taiwan
2015/9-2021/6	Ph.D., Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taiwan
2006/8/1-2009/7/31	Residency of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
2009/8/1-2012/6/30	Chief residency and fellowship of Gastroenterology, Taipei Veterans General Hospital, Taipei, Taiwan
2012/7/1-2013/6/30	Attending Physician, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Veterans General Hospital, Taoyuan branch, Taiwan
2012/8/1-present	Instructor, Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan
2013/7/1-present	Attending Physician, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan
2015/8/1-2019/7/31	Instructor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
2019/8/1-present	Assistant professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
2021/2/1-present	Convener, Hepatocellular Carcinoma Team, Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan
2021/8/1-present	Director, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan

Selected publications:

1. Kao WY, Su CW, Chau GY\*, Lui WY, Wu CW, Wu JC\*. A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery. *World J Surg* 2011; 35: 858-867
2. Kao WY, Chiou YY\*, Hung HH, Chou YH, Su CW\*, Wu JC, Huo TI, Huang YH, Lin HC, Lee SD. Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase-platelet ratio index. *Eur J Gastroenterol Hepatol* 2011; 23: 528-536
3. Kao WY, Chiou YY\*, Hung HH, Su CW\*, Chou YH, Huo TI, Huang YH, Wu WC, Lin HC, Lee SD, Wu JC. Younger Hepatocellular Carcinoma Patients Have Better Prognosis after Percutaneous Radiofrequency Ablation Therapy. *J Clin Gastroenterol* 2012; 46: 62-70

4. Kao WY, Chiou YY\*, Hung HH, Su CW\*, Chou YH, Huo TI, Huang YH, Wu WC, Lin HC, Lee SD, Wu JC. Serum Alpha-fetoprotein Response Can Predict Prognosis in Hepatocellular Carcinoma Patients Undergoing Radiofrequency Ablation Therapy. *Clin Radiol* 2012; 67: 429-436
5. Kao WY, Chao Yee, Chang CC, Li CP, Su CW\*, Huo TI, Huang YH, Chang YJ, Lin HC, Wu JC. Prognosis of Early-Stage Hepatocellular Carcinoma: The Clinical Implications of Substages of Barcelona Clinic Liver Cancer System Based on a Cohort of 1265 Patients. *Medicine* 2015; 94(43): e1929
6. Kao WY†, Su CW†, Chiou YY\*, Chiu NC, Liu CA, Fang KC, Huo TI, Huang YH, Chang CC, Hou MC, Lin HC, Wu JC. Nomograms Based on the Albumin-Bilirubin Grade to Assess the Outcomes of Radiofrequency Ablation for Hepatocellular Carcinoma. *Radiology* 2017;285(2):670-680 †contributed equally to this work.
7. Fang KC, Kao WY, Su CW\*, Chen PC, Lee PC, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC\*. The prognosis of single large hepatocellular carcinoma was distinct from the BCLC stage A or B: The role of albumin-bilirubin grade. *Liver Cancer* 2018; 7: 335–358.
8. Kao WY, Su CW\*, Tan EC\*, Lee PC, Chen PH, Tang JH, Huang YH, Huo TI, Chang CC, Hou MC, Line HC, Wu JC. Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B or C. *Hepatology* 2019;69(3):1151-1164
9. Chen PC, Kao WY, Cheng YL, Wang YJ, Hou MC, Wu JC, Su CW\*. The Correlation between Fatty Liver Disease and Chronic Kidney Disease. *Journal of the Formosan Medical Association* 2020; 119:42-50
10. Kao WY, Chang IW, Chen CL, Su CW, Fang SU, Tang JH, Chang CC, Chang YJ\*, Wang W\*. Fibroscan-based score to predict significant liver fibrosis in morbidly obese patients with nonalcoholic fatty liver disease. *Obesity Surgery* 2020; 30:1249–1257
11. Liu CH, Chen CY, Su WW, Tseng KC, Lo CC, Liu CJ, Chen JJ, Peng CY, Shih YL, Yang SS, Huang CS, Huang KJ, Chang CY, Tsai MC, Kao WY, Fang YJ, Chen PY, Su PY, Tseng CW, Huang JJ, Lee PL, Lai HC, Hsieh TY, Chang CH, Huang YJ, Lee FJ, Chang CC, Kao JH. Sofosbuvir/velpatasvir with or without low-dose ribavirin for 12 weeks in patients with chronic hepatitis C virus infection and severe renal impairment. *Gut* 2022; 71:176–184

Awards:

1. Young Investigator Award of the Asia Pacific Association for the Study of the Liver, 2016
2. Research Award of Taiwan Association for the Study of the Liver, 2018
3. The first place Research Award of Advances in Digestive Medicine, 2019
4. Research Award of Liver Disease Prevention & Treatment Research Foundation, 2021